Other co-occurring genomic alterations such as P53, KEAP1, ATM, PTEN, CDKN2A are common among KRAS-mutant NSCLC, and may play a role in determining response to ICI (100). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.